Enveda Raises $311M in Series E Funding for Nature-Derived AI Drug Development
Biotech startup Enveda has raised $311 million in a Series E funding round, valuing the company at $2 billion. The investment was led by Catalio Capital Management and included participation from Iconiq and other investors. This marks more than double the valuation achieved just one year ago. Founded in 2019 by Viswa Colluru, an early employee of Recursion Pharmaceuticals, Enveda uses AI to discover drugs derived from natural sources like plants and microbes. Although no FDA-approved drug has yet been developed using AI alone, companies such as Enveda are pushing candidates into clinical trials. The startup is currently testing several therapies in human patients, including treatments for severe skin conditions and a medication aimed at maintaining weight loss after discontinuing GLP-1 drugs.
Topics: AI Biotech & Health clinical trials Enveda Startups